FDA tracking hundreds of reports tied to compounded weight-loss drugs, unapproved peptides

The FDA is monitoring hundreds of adverse event reports linked to compounded and unapproved weight-loss drugs, including GLP-1 medications and peptides, warning that these products may pose safety risks and are often not legally approved for human use.

This Wire brief sits within Fusion42's coverage of Health.